News >

Frontline Veliparib Regimen Viable Approach in Advanced Ovarian Cancer

Caroline Seymour
Published: Tuesday, Jan 28, 2020

Robert L. Coleman, MD, FACOG, FACS, professor and Ann Rife Cox Chair in Gynecology, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center

Robert L. Coleman, MD, FACOG, FACS

Data from the phase III VELIA trial demonstrated that the frontline combination of veliparib, carboplatin, and paclitaxel followed by maintenance veliparib is a viable treatment strategy for women with high-grade serous ovarian cancer, particularly those with BRCA1/2 mutations, according to lead study author Robert L. Coleman, MD, FACOG, FACS.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication